Tag Archives: Oncology

Emerging Pharma Leaders: Jamey Millar, GSK

Storytelling, since time immemorial, has served an important role in conveying information, expectations, and obligations. Stories can function as orientation guides, uniting readers or listeners around a common set of assumptions. The best stories also contain an element of surprise, a reminder of the unexpected possibilities, and chance occurrences that bind our lives together. After […]
Posted in leadership | Also tagged , | Leave a comment

The Future of Oncology is Now

Applied Clinical Trials’ Lisa Henderson speaks to Novella Clinical CEO Richard Staub. Last August, Quintiles announced its intention to purchase Novella Clinical, specifically for its focus on small and mid-sized oncology biopharma clients, as well as medical device and diagnostics companies. We checked in with Novella President Richard Staub to discuss post-acquisition life, outsourcing, and […]
Posted in R&D | Also tagged , , | Leave a comment

Breaking Point? The Cost of Oncology Care in the U.S.

The US healthcare system is expected to spend more than $150 billion treating cancer by 2020. In this PharmExec article, Daniele Severi Bruni, Jacob J. Schutz, and Anthony Hewitt of Icon plc ask if we have we have hit a breaking point in the escalating cost of oncology care. Click here for the article.
Posted in healthcare | Tagged | Leave a comment

The Future of Cancer Care?

Human behavior may be the most significant variable in the future of cancer care in two senses: a). The “front-end” or “topographical changes” affecting the identification of need and potential treatment modalities; and b). The care “system” delivery/payment models for care. It will not be about the technology or some great pharmaceutical breakthrough, at least […]
Posted in Guest Blog, healthcare | Also tagged | Leave a comment

Eight Ingredients for a Successful Oncology Drug Development Recipe

by Matthew Cook and Sebastien Morisot In light of the risks and challenges inherent in the development of oncologics, some biopharma companies are beginning to question whether oncology remains an attractive therapeutic area in which to invest limited research, development, and commercialization resources.
Posted in Agency Insight, Biotech, Europe, FDA, Gene therapy, Guest Blog, leadership, Market Access, Orphan Drugs, pricing, R&D, Regulatory, Sales | Also tagged , | Leave a comment
  • Categories

  • Meta